Assessment of response to treatment with the PI3K/mTOR inhibitor BEZ235 with FLT PET in a tumor xenograft model

被引：0
|
作者：
Wanek, T. [1 ]
Fuereder, T. [2 ]
Pflegerl, P. [2 ]
Jaeger-Lansky, A. [2 ]
Hoeflmayer, D. [2 ]
Strommer, S. [2 ]
Mueller, M. [2 ]
Langer, O. [1 ]
Kuntner, C. [1 ]
Wacheck, V. [2 ]
机构：
[1] Austrian Inst Technol, Seibersdorf, Austria
[2] Med Univ Vienna, Vienna, Austria
来源：
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING | 2010年 / 37卷
关键词：
D O I：
暂无
中图分类号：
R8 [特种医学]; R445 [影像诊断学];
学科分类号：
1002 ; 100207 ; 1009 ;
摘要：
引用
收藏
页码：S298 / S299
页数：2
相关论文
共 50 条
  • [1] The Dual PI3K/mTOR Inhibitor BEZ235 Is Effective in Lung Cancer Cell Lines
    Herrera, Vivian Arrias
    Zeindl-Eberhart, Evelyn
    Jung, Andreas
    Huber, Rudolf Maria
    Bergner, Albrecht
    ANTICANCER RESEARCH, 2011, 31 (03) : 849 - 854
  • [2] The PI3K/mTOR inhibitor BEZ235 given twice daily for the treatment of patients (pts) with advanced solid tumors
    Arkenau, Hendrik-Tobias
    Jones, Suzanne Fields
    Kurkjian, Carla
    Infante, Jeffrey R.
    Pant, Shubham
    Burris, Howard A.
    Moore, Kathleen N.
    McMeekin, D. Scott
    Greco, Frank A.
    Ramsey, Sara
    Bendell, Johanna C.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [3] BEZ235, A SELECTIVE PI3K/MTOR INHIBITOR, ENHANCES THE THERAPEUTIC EFFICACY OF DOXORUBICIN IN PANCREATIC CANCER
    Durrant, D.
    Das, A.
    Kukreja, R.
    BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY, 2014, 115 : 303 - 304
  • [4] Radiation Sensitization of HNSCC Cells by the dual PI3K / mTOR Inhibitor BEZ235 as a function of the Cell Cycle
    Brandt, F. W.
    Balzer, V
    Dreffke, K.
    Wittig, A.
    Dikomey, E.
    Arenz, A.
    Schoetz, U.
    Engenhart-Cabillic, R.
    STRAHLENTHERAPIE UND ONKOLOGIE, 2018, 194 : S165 - S165
  • [5] The effect combining the KIT inhibitor Imatinib with the PI3K inhibitor BKM120 or the dual PI3K/mTOR inhibitor BEZ235 on the proliferation of gastrointestinal stromal tumor cell lines
    Li, Fang
    Growney, Joseph
    Battalagine, Linda
    Qiu, Shumei
    Manley, Paul
    Monahan, John
    CANCER RESEARCH, 2012, 72
  • [6] Physiologically based pharmacokinetic model and correlative in vitro assessment of metabolism-based interaction between Everolimus and PI3K/mTOR inhibitor BEZ235
    Moorthy, Ganesh P.
    Abuasal, Bilal
    Sallans, Larry
    Morris, John C.
    Thomas, George
    Desai, Pankaj B.
    CANCER RESEARCH, 2014, 74 (19)
  • [7] Superior efficacy of co-treatment with the dual PI3K/mTOR inhibitor BEZ235 and histone deacetylase inhibitor Trichostatin A against NSCLC
    Piao, Junjie
    Chen, Liyan
    Quan, Taihao
    Li, Longshan
    Quan, Chunji
    Piao, Yingshi
    Jin, Tiefeng
    Lin, Zhenhua
    ONCOTARGET, 2016, 7 (37) : 60169 - 60180
  • [8] Enhanced efficacy of histone deacetylase inhibitor panobinostat combined with dual PI3K/mTOR inhibitor BEZ235 against glioblastoma
    Meng, Wei
    Wang, Baocheng
    Mao, Weiwei
    Wang, Jiajia
    Zhao, Yang
    Li, Qifeng
    Zhang, Chenran
    Ma, Jie
    NAGOYA JOURNAL OF MEDICAL SCIENCE, 2019, 81 (01): : 93 - 102
  • [9] Radiosensitization of prostate cancer cells by the dual PI3K/mTOR inhibitor BEZ235 under normoxic and hypoxic conditions
    Potiron, Vincent A.
    Abderrhamani, Rym
    Giang, Eric
    Chiavassa, Sophie
    Di Tomaso, Emmanuelle
    Maira, Sauveur-Michel
    Paris, Francois
    Supiot, Stephane
    RADIOTHERAPY AND ONCOLOGY, 2013, 106 (01) : 138 - 146
  • [10] Preclinical evaluation of the mTOR-PI3K inhibitor BEZ235 in nasopharyngeal cancer models
    Ma, Brigette B. Y.
    Lui, Vivian W. Y.
    Hui, Connie W. C.
    Lau, Cecilia P. Y.
    Wong, Chi H.
    Hui, Edwin P.
    Ng, Margaret H. L.
    Cheng, Suk H.
    Tsao, Sai W.
    Tsang, Chi-Man
    Cheung, Crystal S. F.
    Ho, Kakiu
    Chan, Anthony T. C.
    CANCER LETTERS, 2014, 343 (01) : 24 - 32
12345